Drug intelligence / Profile preview

PentaHibe

Development stage: Preclinical
Lead developer: Pharmacosmos
Modality: Small Molecules
Administration: Intravenous

Overview

PentaHibe is a trademarked pharmaceutical candidate developed by Pharmacosmos, a company specializing in carbohydrate chemistry and intravenous iron therapies. While specific clinical details and molecular structures have not been publicly disclosed, the trademark is registered for the treatment of iron deficiency and iron deficiency anemia. Given Pharmacosmos's established portfolio, which includes products like ferric derisomaltose (Monoferric) and iron dextran (CosmoFer), PentaHibe is likely a next-generation iron-carbohydrate complex designed for intravenous iron replacement. The drug was previously associated with AMAG Pharmaceuticals through their commercial partnership for iron deficiency treatments in the United States.

Brand names: PentaHibe

Beyond the preview

Go deeper on PentaHibe.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PentaHibe.

Explore the full profile